GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Merrimack Pharmaceuticals Inc (NAS:MACK) » Definitions » Shiller PE Ratio

Merrimack Pharmaceuticals (Merrimack Pharmaceuticals) Shiller PE Ratio : 11.73 (As of Jun. 09, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Merrimack Pharmaceuticals Shiller PE Ratio?

As of today (2024-06-09), Merrimack Pharmaceuticals's current share price is $15.13. Merrimack Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 was $1.29. Merrimack Pharmaceuticals's Shiller PE Ratio for today is 11.73.

The historical rank and industry rank for Merrimack Pharmaceuticals's Shiller PE Ratio or its related term are showing as below:

MACK' s Shiller PE Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 11.72
Current: 11.72

During the past years, Merrimack Pharmaceuticals's highest Shiller PE Ratio was 11.72. The lowest was 0.00. And the median was 0.00.

MACK's Shiller PE Ratio is ranked better than
88.31% of 154 companies
in the Biotechnology industry
Industry Median: 30.475 vs MACK: 11.72

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Merrimack Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was $13.930. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $1.29 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Merrimack Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Merrimack Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merrimack Pharmaceuticals Shiller PE Ratio Chart

Merrimack Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Merrimack Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 11.44

Competitive Comparison of Merrimack Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Merrimack Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merrimack Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Merrimack Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Merrimack Pharmaceuticals's Shiller PE Ratio falls into.



Merrimack Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Merrimack Pharmaceuticals's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=15.13/1.29
=11.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merrimack Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Merrimack Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=13.93/131.7762*131.7762
=13.930

Current CPI (Mar. 2024) = 131.7762.

Merrimack Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -1.700 100.560 -2.228
201409 -2.700 100.428 -3.543
201412 -0.900 99.070 -1.197
201503 -3.200 99.621 -4.233
201506 -2.100 100.684 -2.749
201509 -3.800 100.392 -4.988
201512 -4.100 99.792 -5.414
201603 -3.400 100.470 -4.459
201606 -4.000 101.688 -5.184
201609 -2.330 101.861 -3.014
201612 -2.500 101.863 -3.234
201703 -2.270 102.862 -2.908
201706 38.620 103.349 49.243
201709 0.240 104.136 0.304
201712 -1.080 104.011 -1.368
201803 -1.330 105.290 -1.665
201806 -1.330 106.317 -1.648
201809 0.300 106.507 0.371
201812 -0.660 105.998 -0.821
201903 -0.780 107.251 -0.958
201906 -0.710 108.070 -0.866
201909 -0.050 108.329 -0.061
201912 0.240 108.420 0.292
202003 0.020 108.902 0.024
202006 -0.090 108.767 -0.109
202009 -0.080 109.815 -0.096
202012 -0.090 109.897 -0.108
202103 -0.050 111.754 -0.059
202106 -0.060 114.631 -0.069
202109 -0.040 115.734 -0.046
202112 -0.030 117.630 -0.034
202203 -0.010 121.301 -0.011
202206 -0.040 125.017 -0.042
202209 -0.030 125.227 -0.032
202212 -0.030 125.222 -0.032
202303 -0.020 127.348 -0.021
202306 -0.030 128.729 -0.031
202309 -0.020 129.860 -0.020
202312 -0.010 129.419 -0.010
202403 13.930 131.776 13.930

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Merrimack Pharmaceuticals  (NAS:MACK) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Merrimack Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Merrimack Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Merrimack Pharmaceuticals (Merrimack Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
One Broadway, 14th Floor, Cambridge, MA, USA, 02142
Merrimack Pharmaceuticals Inc is a biotechnology company that discovers, develops, and commercializes innovative medicines that consist of novel therapeutics paired with diagnostics to treat cancer. The company's core approach to systems biology is to apply multidisciplinary capabilities to build functional and predictive computational models of biological systems, such as cell signaling networks. Merrimack also enters into third-party agreements to further process and commercialize its products.
Executives
Eric Andersen director, other: See Remarks 1507 BERKELEY ST, SUITE 7, SANTA MONICA X1 90404
Gary L Crocker director, officer: President MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Noah G. Levy director, other: See Remarks 60 EAST 42ND ST, 9TH FLOOR, NEW YORK NY 10165
Ana Radeljevic director 2430 BEACON STREET, UNIT 201, CHESTNUT HILL MA 02467
Ulrik B. Nielsen director MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Russell T Ray director 2525 DUPONT DR, IRVINE CA 92612
Newtyn Capital Partners, Lp other: See Remarks 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Ledo Capital, Llc other: See Remarks 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Newtyn Te Partners, Lp other: See Remarks 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Newtyn Partners, Lp other: See Remarks 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Western Standard Partners Qp, L.p. other: See Remarks 5900 WILSHIRE BLVD, SUITE 650, LOS ANGELES CA 90036
Western Standard Partners Lp other: See Remarks 5900 WILSHIRE BLVD, SUITE 650, LOS ANGELES CA 90036
Western Standard Llc other: See Remarks 5757 WILSHIRE BLVD, SUITE 636, LOS ANGELES CA 90036
Newtyn Management, Llc other: See Remarks 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
22nw Gp, Inc. 10 percent owner, other: See Explanation of Responses 1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107

Merrimack Pharmaceuticals (Merrimack Pharmaceuticals) Headlines

From GuruFocus

Merrimack Reports Third Quarter 2022 Financial Results

By Business Wire Business Wire 11-03-2022

Merrimack Reports First Quarter 2023 Financial Results

By Business Wire Business Wire 05-04-2023

Merrimack Reports Second Quarter 2021 Financial Results

By Business Wire Business Wire 08-05-2021

Merrimack Reports First Quarter 2019 Financial Results

By PRNewswire PRNewswire 05-10-2019

JFL Capital Ends Campaign at Merrimack

By PRNewswire PRNewswire 09-25-2019

Merrimack Discontinues Development of MM-310

By PRNewswire PRNewswire 04-05-2019

Merrimack Reports First Quarter 2022 Financial Results

By Business Wire Business Wire 05-05-2022